Z

Zevra Therapeutics Inc
NASDAQ:ZVRA

Watchlist Manager
Zevra Therapeutics Inc
NASDAQ:ZVRA
Watchlist
Price: 9.03 USD 4.27% Market Closed
Market Cap: 475.2m USD
Have any thoughts about
Zevra Therapeutics Inc?
Write Note

Zevra Therapeutics Inc
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Zevra Therapeutics Inc
Cash Equivalents Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Z
Zevra Therapeutics Inc
NASDAQ:ZVRA
Cash Equivalents
$39.3m
CAGR 3-Years
-33%
CAGR 5-Years
40%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Cash Equivalents
$4.8B
CAGR 3-Years
32%
CAGR 5-Years
27%
CAGR 10-Years
-10%
Bristol-Myers Squibb Co
NYSE:BMY
Cash Equivalents
$7.9B
CAGR 3-Years
-16%
CAGR 5-Years
-24%
CAGR 10-Years
5%
Pfizer Inc
NYSE:PFE
Cash Equivalents
$1.1B
CAGR 3-Years
-19%
CAGR 5-Years
-18%
CAGR 10-Years
-8%
Merck & Co Inc
NYSE:MRK
Cash Equivalents
$14.6B
CAGR 3-Years
13%
CAGR 5-Years
13%
CAGR 10-Years
3%
Eli Lilly and Co
NYSE:LLY
Cash Equivalents
$3.4B
CAGR 3-Years
-4%
CAGR 5-Years
17%
CAGR 10-Years
1%

See Also

What is Zevra Therapeutics Inc's Cash Equivalents?
Cash Equivalents
39.3m USD

Based on the financial report for Jun 30, 2024, Zevra Therapeutics Inc's Cash Equivalents amounts to 39.3m USD.

What is Zevra Therapeutics Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
40%

Over the last year, the Cash Equivalents growth was -41%. The average annual Cash Equivalents growth rates for Zevra Therapeutics Inc have been -33% over the past three years , 40% over the past five years .

Back to Top